Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 34 n° 316

Therapy for Women with Advanced Breast Cancer

Posted by fidest press agency su mercoledì, 9 ottobre 2019

Context Therapeutics, a clinical-stage biopharmaceutical company dedicated to advancing treatments for hormone driven cancers, today announced a Phase 2 clinical collaboration with the Wisconsin Oncology Network. This clinical collaboration will evaluate whether the addition of Apristorto the antiestrogen, fulvestrant, can enhance outcomes for patients with metastatic breast cancer whose cancer has progressed on prior therapies.
The study will be coordinated by the Study Chair, Dr. Sailaja Kamaraju, an Associate Professor of Medical Oncology at the Medical College of Wisconsin, and study’s Primary Investigator, Dr. Kari Wisinski, Associate Professor of Medical Oncology at the University of Wisconsin Carbone Cancer Center. Final study design and other details will be announced upon enrollment of the first patient, expected in early 2020. “The majority of breast cancer patients have hormone driven breast cancer. The hormones estrogen and progesterone drive breast cancer progression in those patients, but antiestrogens are the only antihormonal therapy available to clinicians. Therefore, treatment of those patients to date has consisted of antiestrogens alone or in combination with agents, including CDK4/6 inhibitors, that enhance the antitumor activity of antiestrogens. Given the broad use of antiestrogens, antiestrogen resistance is now a major clinical challenge,” said Dr. Kamaraju. “We believe that a progesterone receptor antagonist has the potential to address antiestrogen resistance, which we believe will lead to better outcomes for patients. This study, run in parallel with other Apristor breast cancer studies, including a window of opportunity (neoadjuvant) study at SOLTI and a first line (1L) biochemical recurrence study at Memorial Sloan Kettering Cancer Center, will provide clinicians with a complete picture of how Apristor works in advanced ER+,PR+,HER2- breast cancer and inform the design of a future Phase 3 trial.”


Inserisci i tuoi dati qui sotto o clicca su un'icona per effettuare l'accesso:

Logo di

Stai commentando usando il tuo account Chiudi sessione /  Modifica )

Foto Twitter

Stai commentando usando il tuo account Twitter. Chiudi sessione /  Modifica )

Foto di Facebook

Stai commentando usando il tuo account Facebook. Chiudi sessione /  Modifica )

Connessione a %s...

%d blogger hanno fatto clic su Mi Piace per questo: